Angiogenesis in diabetes and obesity

Reviews in Endocrine and Metabolic Disorders

Volumn 16, Issue 1, 2015, Pages 67-75

  Cheng, Rui ^a   Ma, Jian xing ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Angiogenesis; Diabetes mellitus; Obesity

Indexed keywords

KALLISTATIN; PIGMENT EPITHELIUM DERIVED FACTOR; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADIPOSE TISSUE; ANGIOGENESIS; DIABETES MELLITUS; DIABETIC PATIENT; DIABETIC RETINOPATHY; HUMAN; NON PROLIFERATIVE DIABETIC RETINOPATHY; NONHUMAN; OBESITY; REVIEW; WOUND HEALING IMPAIRMENT; DIABETIC ANGIOPATHY; NEOVASCULARIZATION (PATHOLOGY); NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY;

DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; OBESITY;

EID: 84925503217     PISSN: 13899155     EISSN: 15732606     Source Type: Journal    
DOI: 10.1007/s11154-015-9310-7     Document Type: Review

References (157)

1. Assoc AD. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37:S81–90.
2. Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011;378:31–40.
3. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–53.
4. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87:4–14.
5. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults--the evidence report. National Institutes of Health. Obes Res. 1998;6 Suppl 2:51S-209S.
6. Mokdad AH, Bowman BA, Ford ES, et al. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001;286:1195–200.
7. Grundy SM. Metabolic complications of obesity. Endocrine. 2000;13:155–65.
8. Cade WT. Diabetes-related microvascular and macrovascular diseases in the physical therapy setting. Phys Ther. 2008;88:1322–35.
9. Folkman J. Angiogenesis. Annu Rev Med. 2006;57:1–18.
10. Risau W, Flamme I. Vasculogenesis. Annu Rev Cell Dev Biol. 1995;11:73–91.
11. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol. 2001;280:C1358–66.
12. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2002;29:15–8.
13. Ribatti D, Vacca A, Roccaro AM, et al. Erythropoietin as an angiogenic factor. Eur J Clin Invest. 2003;33:891–6.
14. Arcasoy MO, Hardee ME, Jiang XH, et al. Role of erythropoietin as an angiogenic factor and target in cancer. Blood. 2006;108:127a-a.
15. Gao GQ, Li Y, Zhang DC, et al. Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization. FEBS Lett. 2001;489:270–6.
16. Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science. 1999;285:245–8.
17. Miao RQ, Agata J, Chao L, et al. Kallistatin is a new inhibitor of angiogenesis and tumor growth. Blood. 2002;100:3245–52.
18. Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med. 2002;6:1–12.
19. Costa PZ, Soares R. Neovascularization in diabetes and its complications. Unraveling the angiogenic paradox. Life Sci. 2013;92:1037–45.
20. Martin A, Komada MR, Sane DC. Abnormal angiogenesis in diabetes mellitus. Med Res Rev. 2003;23:117–45.
21. Christiaens V, Lijnen HR. Angiogenesis and development of adipose tissue. Mol Cell Endocrinol. 2010;318:2–9.
22. Cao Y. Angiogenesis modulates adipogenesis and obesity. J Clin Invest. 2007;117:2362–8.
23. Rosberger DF. Diabetic retinopathy current concepts and emerging therapy. Endocrinol Metab Clin North Am. 2013;42:721.
24. The relationship of glycemic exposure (Hba(1c)) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes. 1995;44:968–83.
25. Diabetic Retinopathy Clinical Research N. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. JAMA Ophthalmol. 2013;131:283–93.
26. Schmidinger G, Maar N, Bolz M, et al. Repeated intravitreal bevacizumab (Avastin((R))) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation. Acta Ophthalmol. 2011;89:76–81.
27. Bin CW, Moon JW, Kim HC. Intravitreal triamcinolone and bevacizumab as adjunctive treatments to panretinal photocoagulation in diabetic retinopathy. Br J Ophthalmol. 2010;94:858–63.
28. Shin YW, Lee YJ, Lee BR, et al. Effects of an intravitreal bevacizumab injection combined with panretinal photocoagulation on high-risk proliferative diabetic retinopathy. Korean J Ophthalmol. 2009;23:266–72.
29. Cho WB, Oh SB, Moon JW, et al. Panretinal photocoagulation combined with intravitreal bevacizumab in high-risk proliferative diabetic retinopathy. Retina. 2009;29:516–22.
30. Scott IU, Edwards AR, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology. 2007;114:1860–7.
31. Cavanagh PR, Buse JB, Frykberg RG, et al. Consensus development conference on diabetic foot wound care - 7–8 April 1999, Boston, Massachusetts. J Am Podiatr Med Assoc. 1999;89:475–83.
32. Calle-Pascual AL, Garcia-Torre N, Moraga I, et al. Epidemiology of nontraumatic lower-extremity amputation in area 7, Madrid, between 1989 and 1999—a population-based study. Diabetes Care. 2001;24:1686–9.
33. Lavery LA, Armstrong DG, Wunderlich RP, et al. Diabetic foot syndrome—evaluating the prevalence and incidence of foot pathology in Mexican Americans and non-Hispanic whites from a diabetes disease management cohort. Diabetes Care. 2003;26:1435–8.
34. Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA. 2005;293:217–28.
35. Kolluru GK, Bir SC, Kevil CG. Endothelial dysfunction and diabetes: effects on angiogenesis, vascular remodeling, and wound healing. Int J Vasc Med. 2012;2012:918267.
36. Tie L, Li XJ, Wang X, et al. Endothelium-specific GTP cyclohydrolase I overexpression accelerates refractory wound healing by suppressing oxidative stress in diabetes. Am J Physiol Endocrinol Metab. 2009;296:E1423–9.
37. Bao P, Kodra A, Tomic-Canic M, et al. The role of vascular endothelial growth factor in wound healing. J Surg Res. 2009;153:347–58.
38. Machado MJ, Watson MG, Devlin AH, et al. Dynamics of angiogenesis during wound healing: a coupled in vivo and in silico study. Microcirculation. 2011;18:183–97.
39. Tonnesen MG, Feng X, Clark RA. Angiogenesis in wound healing. J Investig Dermatol Symp Proc. 2000;5:40–6.
40. Qi W, Yang C, Dai Z, et al. High levels of pigment epithelium-derived factor in diabetes impair wound healing through suppression of Wnt signaling. Diabetes. 2014.
41. McBride JD, Jenkins AJ, Liu XC, et al. Elevated circulation levels of an antiangiogenic SERPIN in patients with diabetic microvascular complications impair wound healing through suppression of Wnt signaling. J Investi Dermatol. 2014;134:1725–34.
42. Galiano RD, Tepper OM, Pelo CR, et al. Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells. Am J Pathol. 2004;164:1935–47.
43. Brem H, Kodra A, Golinko MS, et al. Mechanism of sustained release of vascular endothelial growth factor in accelerating experimental diabetic healing. J Invest Dermatol. 2009;129:2275–87.
44. Brem H, Tomic-Canic M. Cellular and molecular basis of wound healing in diabetes. J Clin Investig. 2007;117:1219–22.
45. Gallagher KA, Liu ZJ, Xiao M, et al. Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1 alpha. J Clin Investig. 2007;117:1249–59.
46. Frank S, Stallmeyer B, Kampfer H, et al. Nitric oxide triggers enhanced induction of vascular endothelial growth factor expression in cultured keratinocytes (HaCaT) and during cutaneous wound repair. FASEB J. 1999;13:2002–14.
47. Braverman IM, Sibley J, Keh A. Ultrastructural analysis of the endothelial pericyte relationship in diabetic cutaneous vessels. J Investig Dermatol. 1990;95:147–53.
48. Hoeben A, Landuyt B, Highley MS, et al. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 2004;56:549–80.
49. Chiarelli F, Spagnoli A, Basciani F, et al. Vascular endothelial growth factor (VEGF) in children, adolescents and young adults with Type 1 diabetes mellitus: relation to glycaemic control and microvascular complications. Diabet Med. 2000;17:650–6.
50. Kocak N, Alacacioglu I, Kaynak S, et al. Comparison of vitreous and plasma levels of vascular endothelial growth factor, interleukin-6 and hepatocyte growth factor in diabetic and non-diabetic retinal detachment cases. Ann Ophthalmol (Skokie). 2010;42:10–4.
51. Praidou A, Papakonstantinou E, Androudi S, et al. Vitreous and serum levels of vascular endothelial growth factor and platelet-derived growth factor and their correlation in patients with non-proliferative diabetic retinopathy and clinically significant macula oedema. Acta Ophthalmol. 2011;89:248–54.
52. Watanabe D, Suzuma K, Suzuma I, et al. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am J Ophthalmol. 2005;139:476–81.
53. Funatsu H, Yamashita H, Ikeda T, et al. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmol. 2003;110:1690–6.
54. Funatsu H, Yamashita H, Nakamura S, et al. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmol. 2006;113:294–301.
55. Funatsu H, Yamashita H, Sakata K, et al. Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema. Ophthalmol. 2005;112:806–16.
56. Noma H, Funatsu H, Mimura T, et al. Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Ophthalmol. 2009;116:87–93.
57. Hernandez C, Burgos R, Canton A, et al. Vitreous levels of vascular cell adhesion molecule and vascular endothelial growth factor in patients with proliferative diabetic retinopathy: a case–control study. Diabetes Care. 2001;24:516–21.
58. Burgos R, Simo R, Audi L, et al. Vitreous levels of vascular endothelial growth factor are not influenced by its serum concentrations in diabetic retinopathy. Diabetologia. 1997;40:1107–9.
59. Sato H, Abe T, Wakusawa R, et al. Vitreous levels of vasohibin-1 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Diabetologia. 2009;52:359–61.
60. Sato T, Kusaka S, Shimojo H, et al. Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity. Ophthalmology. 2009;116:1599–603.
61. Ogata N, Nishikawa M, Nishimura T, et al. Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy. Am J Ophthalmol. 2002;134:348–53.
62. Bai Y, Ma JX, Guo J, et al. Muller cell-derived VEGF is a significant contributor to retinal neovascularization. J Pathol. 2009;219:446–54.
63. Rodrigues M, Xin X, Jee K, et al. VEGF secreted by hypoxic Muller cells induces MMP-2 expression and activity in endothelial cells to promote retinal neovascularization in proliferative diabetic retinopathy. Diabetes. 2013;62:3863–73.
64. Wang J, Xu X, Elliott MH, et al. Muller cell-derived VEGF is essential for diabetes-induced retinal inflammation and vascular leakage. Diabetes. 2010;59:2297–305.
65. Mahdy RA, Nada WM, Hadhoud KM, et al. The role of vascular endothelial growth factor in the progression of diabetic vascular complications. Eye. 2010;24:1576–84.
66. Semeraro F, Cancarini A, Morescalchi F, et al. Serum and intraocular concentrations of erythropoietin and vascular endothelial growth factor in patients with type 2 diabetes and proliferative retinopathy. Diabetes Metab. 2014.
67. Frank S, Hubner G, Breier G, et al. Regulation of vascular endothelial growth-factor expression in cultured keratinocytes—implications for normal and impaired wound-healing. J Biol Chem. 1995;270:12607–13.
68. Shukla A, Dubey MP, Srivastava R, et al. Differential expression of proteins during healing of cutaneous wounds in experimental normal and chronic models. Biochem Biophys Res Commun. 1998;244:434–9.
69. Tombran-Tink J, Johnson LV. Neuronal differentiation of retinoblastoma cells induced by medium conditioned by human RPE cells. Invest Ophthalmol Vis Sci. 1989;30:1700–7.
70. Tombran-Tink J, Chader GG, Johnson LV. PEDF: a pigment epithelium-derived factor with potent neuronal differentiative activity. Exp Eye Res. 1991;53:411–4.
71. Tombran-Tink J, Barnstable CJ. PEDF: a multifaceted neurotrophic factor. Nat Rev Neurosci. 2003;4:628–36.
72. Becerra SP, Notario V. The effects of PEDF on cancer biology: mechanisms of action and therapeutic potential. Nat Rev Cancer. 2013;13:258–71.
73. Chojnacki A, Weiss S. Pigment epithelium-derived growth factor: modulating adult neural stem cell self-renewal. Nat Neurosci. 2009;12:1481–3.
74. Ho TC, Chen SL, Wu JY, et al. PEDF promotes self-renewal of limbal stem cell and accelerates corneal epithelial wound healing. Stem Cells. 2013;31:1775–84.
75. Park K, Jin J, Hu Y, et al. Overexpression of pigment epithelium-derived factor inhibits retinal inflammation and neovascularization. Am J Pathol. 2011;178:688–98.
76. Zhang SX, Wang JJ, Dashti A, et al. Pigment epithelium-derived factor mitigates inflammation and oxidative stress in retinal pericytes exposed to oxidized low-density lipoprotein. J Mol Endocrinol. 2008;41:135–43.
77. Crowe S, Wu LE, Economou C, et al. Pigment epithelium-derived factor contributes to insulin resistance in obesity. Cell Metab. 2009;10:40–7.
78. Mohan N, Monickaraj F, Balasubramanyam M, et al. Imbalanced levels of angiogenic and angiostatic factors in vitreous, plasma and postmortem retinal tissue of patients with proliferative diabetic retinopathy. J Diabetes Complications. 2012;26:435–41.
79. Zheng BQ, Li T, Chen HB, et al. Correlation between Ficolin-3 and vascular endothelial growth factor-to-pigment epithelium-derived factor ratio in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 2011;152:1039–43.
80. Park K, Lee K, Zhang B, et al. Identification of a novel inhibitor of the canonical Wnt pathway. Mol Cell Biol. 2011;31:3038–51.
81. Jenkins AJ, Zhang S, Rowley K, et al. Increased serum pigment epithelium-derived growth factor levels in type 1 diabetes with microvascular complications. Diabetes. 2006;55:A504-A.
82. Jenkins AJ, Zhang SX, Rowley KG, et al. Increased serum pigment epithelium-derived factor is associated with microvascular complications, vascular stiffness and inflammation in type 1 diabetes. Diabet Med. 2007;24:1345–51.
83. Jenkins AJ, Fu D, Azar M, et al. Clinical correlates of serum pigment epithelium-derived factor in type 2 diabetes patients. J Diabetes Complications. 2014;28:353–9.
84. Tryggestad JB, Wang JJ, Zhang SX, et al. Elevated plasma pigment epithelium-derived factor in children with type 2 diabetes mellitus is attributable to obesity. Pediatr Diabetes. 2014.
85. Wang P, Smit E, Brouwers MCGJ, et al. Plasma pigment epithelium-derived factor is positively associated with obesity in Caucasian subjects, in particular with the visceral fat depot. Eur J Endocrinol. 2008;159:713–8.
86. Yamagishi S, Adachi H, Abe A, et al. Elevated serum levels of pigment epithelium-derived factor in the metabolic syndrome. J Clin Endocrinol Metab. 2006;91:2447–50.
87. Dai Z, Qi W, Li C, et al. Dual regulation of adipose triglyceride lipase by pigment epithelium-derived factor: a novel mechanistic insight into progressive obesity. Mol Cell Endocrinol. 2013;377:123–34.
88. Zhang SX, Wang JJ, Gao G, et al. Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy. J Mol Endocrinol. 2006;37:1–12.
89. Chao J, Tillman DM, Wang M, et al. Identification of a new tissue-kallikrein-binding protein. Biochem J. 1986;239:325–31.
90. Wolf WC, Harley RA, Sluce D, et al. Localization and expression of tissue kallikrein and kallistatin in human blood vessels. J Histochem Cytochem. 1999;47:221–8.
91. Liu X, Zhang B, McBride JD, et al. Antiangiogenic and antineuroinflammatory effects of kallistatin through interactions with the canonical Wnt pathway. Diabetes. 2013;62:4228–38.
92. Lu L, Yang Z, Zhu B, et al. Kallikrein-binding protein suppresses growth of hepatocellular carcinoma by anti-angiogenic activity. Cancer Lett. 2007;257:97–106.
93. Zhu B, Lu L, Cai W, et al. Kallikrein-binding protein inhibits growth of gastric carcinoma by reducing vascular endothelial growth factor production and angiogenesis. Mol Cancer Ther. 2007;6:3297–306.
94. Ma JX, King LP, Yang Z, et al. Kallistatin in human ocular tissues: reduced levels in vitreous fluids from patients with diabetic retinopathy. Curr Eye Res. 1996;15:1117–23.
95. Jenkins A, Januszewski A, Mcbride J, et al. Increased serum kallistatin levels in patients with type 1 diabetes and its vascular complications. Diabetes. 2009;58:A214–A5.
96. Schrufer TL, Antonetti DA, Sonenberg N, et al. Ablation of 4E-BP1/2 prevents hyperglycemia-mediated induction of VEGF expression in the rodent retina and in Muller cells in culture. Diabetes. 2010;59:2107–16.
97. Abcouwer SF, Marjon PL, Loper RK, et al. Response of VEGF expression to amino acid deprivation and inducers of endoplasmic reticulum stress. Invest Ophthalmol Vis Sci. 2002;43:2791–8.
98. Kase S, He SK, Sonoda S, et al. Alpha B-crystallin regulation of angiogenesis by modulation of VEGF. Blood. 2010;115:3398–406.
99. Tischer E, Mitchell R, Hartman T, et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem. 1991;266:11947–54.
100. Akiri G, Nahari D, Finkelstein Y, et al. Regulation of vascular endothelial growth factor (VEGF) expression is mediated by internal initiation of translation and alternative initiation of transcription. Oncogene. 1998;17:227–36.
101. Pages G, Pouyssegur J. Transcriptional regulation of the vascular endothelial growth factor gene—a concert of activating factors. Cardiovasc Res. 2005;65:564–73.
102. Clifford RL, Deacon K, Knox AJ. Novel regulation of vascular endothelial growth factor-A (VEGF-A) by transforming growth factor (beta)1: requirement for Smads, (beta)-CATENIN, AND GSK3(beta). J Biol Chem. 2008;283:35337–53.
103. Xie K, Wei D, Shi Q, et al. Constitutive and inducible expression and regulation of vascular endothelial growth factor. Cytokine Growth Factor Rev. 2004;15:297–324.
104. Shima DT, Kuroki M, Deutsch U, et al. The mouse gene for vascular endothelial growth factor. Genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences. J Biol Chem. 1996;271:3877–83.
105. Ko HM, Jung HH, Seo KH, et al. Platelet-activating factor-induced NF-kappa B activation enhances VEGF expression through a decrease in p53 activity. FEBS Lett. 2006;580:3006–12.
106. Xie TX, Xia Z, Zhang N, et al. Constitutive NF-kappaB activity regulates the expression of VEGF and IL-8 and tumor angiogenesis of human glioblastoma. Oncol Rep. 2010;23:725–32.
107. Kiriakidis S, Andreakos E, Monaco C, et al. VEGF expression in human macrophages is NF-kappa B-dependent: studies using adenoviruses expressing the endogenous NF-kappa B inhibitor I kappa B alpha and a kinase-defective form of the I kappa B kinase 2. J Cell Sci. 2003;116:665–74.
108. Nagineni CN, Kommineni VK, William A, et al. Regulation of VEGF expression in human retinal cells by cytokines: implications for the role of inflammation in age-related macular degeneration. J Cell Physiol. 2012;227:116–26.
109. Fujioka S, Niu JG, Schmidt C, et al. NF-KB and AP-1 connection: mechanism of NF-kappa B-Dependent regulation of AP-1 activity. Mol Cell Biol. 2004;24:7806–19.
110. Yan SD, Schmidt AM, Anderson GM, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end-products with their receptors binding-proteins. J Biol Chem. 1994;269:9889–97.
111. Neumann A, Schinzel R, Palm D, et al. High molecular weight hyaluronic acid inhibits advanced glycation endproduct-induced NF-kappa B activation and cytokine expression. FEBS Lett. 1999;453:283–7.
112. Zhu P, Ren M, Yang C, et al. Involvement of RAGE, MAPK and NF-kappaB pathways in AGEs-induced MMP-9 activation in HaCaT keratinocytes. Exp Dermatol. 2012;21:123–9.
113. Hirota K, Semenza GL. Regulation of angiogenesis by hypoxia-inducible factor 1. Crit Rev Oncol Hematol. 2006;59:15–26.
114. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004;20:781–810.
115. Zhang XB, Gaspard JP, Chung DC. Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. Cancer Res. 2001;61:6050–4.
116. Moon RT, Bowerman B, Boutros M, et al. The promise and perils of Wnt signaling through beta-catenin. Science. 2002;296:1644–6.
117. Ma JX, Hu Y, Zhou T, et al. Activation of the Wnt pathway in the retina, a new pathogenic mechanism for diabetic retinopathy. Diabetes. 2009;58:A228-A.
118. Chen Y, Hu Y, Zhou T, et al. Activation of the Wnt pathway plays a pathogenic role in diabetic retinopathy in humans and animal models. Am J Pathol. 2009;175:2676–85.
119. Lee K, Hu Y, Ding LX, et al. Therapeutic potential of a monoclonal antibody blocking the Wnt pathway in diabetic retinopathy. Diabetes. 2012;61:2948–57.
120. Fathke C, Wilson L, Shah K, et al. Wnt signaling induces epithelial differentiation during cutaneous wound healing. BMC Cell Biol. 2006;7.
121. Wu X, Shen QT, Oristian DS, et al. Skin stem cells orchestrate directional migration by regulating microtubule-ACF7 connections through GSK3beta. Cell. 2011;144:341–52.
122. Whyte JL, Smith AA, Helms JA. Wnt signaling and injury repair. Cold Spring Harb Perspect Biol. 2012;4.
123. Hanai J, Gloy J, Karumanchi SA, et al. Endostatin is a potential inhibitor of Wnt signaling. J Cell Biol. 2002;158:529–39.
124. Cao Y. Angiogenesis modulates adipogenesis and obesity. J Clin Investig. 2007;117:2362–8.
125. Rupnick MA, Panigrahy D, Zhang CY, et al. Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci U S A. 2002;99:10730–5.
126. Tam J, Duda DG, Perentes JY, et al. Blockade of VEGFR2 and not VEGFR1 can limit diet-induced fat tissue expansion: role of local versus bone marrow-derived endothelial cells. PLoS One. 2009;4:e4974.
127. Brakenhielm E, Cao R, Gao B, et al. Angiogenesis inhibitor, TNP-470, prevents diet-induced and genetic obesity in mice. Circ Res. 2004;94:1579–88.
128. Demeulemeester D, Collen D, Lijnen HR. Effect of matrix metalloproteinase inhibition on adipose tissue development. Biochem Biophys Res Commun. 2005;329:105–10.
129. Lijnen HR, Maquoi E, Hansen LB, et al. Matrix metalloproteinase inhibition impairs adipose tissue development in mice. Arterioscler Thromb Vasc Biol. 2002;22:374–9.
130. Van Hul M, Lijnen HR. Matrix metalloproteinase inhibition impairs murine adipose tissue development independently of leptin. Endocr J. 2011;58:101–7.
131. Cao YH. Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases. Nat Rev Drug Discov. 2010;9:107–15.
132. Cannon B, Nedergaard J. Brown adipose tissue: function and physiological significance. Physiol Rev. 2004;84:277–359.
133. Zingaretti MC, Crosta F, Vitali A, et al. The presence of UCP1 demonstrates that metabolically active adipose tissue in the neck of adult humans truly represents brown adipose tissue. FASEB J. 2009;23:3113–20.
134. Vijgen GH, Bouvy ND, Teule GJ, et al. Increase in brown adipose tissue activity after weight loss in morbidly obese subjects. J Clin Endocrinol Metab. 2012;97:E1229–33.
135. Vijgen GH, Bouvy ND, Teule GJ, et al. Brown adipose tissue in morbidly obese subjects. PLoS One. 2011;6:e17247.
136. van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM, et al. Cold-activated brown adipose tissue in healthy men. N Engl J Med. 2009;360:1500–8.
137. Tam CS, Lecoultre V, Ravussin E. Brown adipose tissue: mechanisms and potential therapeutic targets. Circulation. 2012;125:2782–91.
138. Mohamed-Ali V, Pinkney JH, Coppack SW. Adipose tissue as an endocrine and paracrine organ. Int J Obes (Lond). 1998;22:1145–58.
139. Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest. 2003;112:1785–8.
140. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2004;92:347–55.
141. Trayhurn P. Hypoxia and adipose tissue function and dysfunction in obesity. Physiol Rev. 2013;93:1–21.
142. Ye J. Emerging role of adipose tissue hypoxia in obesity and insulin resistance. Int J Obes (Lond). 2009;33:54–66.
143. O’Rourke RW, White AE, Metcalf MD, et al. Hypoxia-induced inflammatory cytokine secretion in human adipose tissue stromovascular cells. Diabetologia. 2011;54:1480–90.
144. Gealekman O, Guseva N, Hartigan C, et al. Depot-specific differences and insufficient subcutaneous adipose tissue angiogenesis in human obesity. Circulation. 2011;123:186–U73.
145. Gavin TP, Stallings HW, Zwetsloot KA, et al. Lower capillary density but no difference in VEGF expression in obese vs. lean young skeletal muscle in humans. J Appl Physiol. 2005;98:315–21.
146. Pasarica M, Sereda OR, Redman LM, et al. Reduced adipose tissue oxygenation in human obesity: evidence for rarefaction, macrophage chemotaxis, and inflammation without an angiogenic response. Diabetes. 2009;58:718–25.
147. Lash JM, Sherman WM, Hamlin RL. Capillary basement-membrane thickness and capillary density in sedentary and trained obese Zucker rats. Diabetes. 1989;38:854–60.
148. Pang C, Gao ZG, Yin J, et al. Macrophage infiltration into adipose tissue may promote angiogenesis for adipose tissue remodeling in obesity. Am J Physiol Endocrinol Metab. 2008;295:E313–E22.
149. Spencer M, Unal R, Zhu BB, et al. Adipose tissue extracellular matrix and vascular abnormalities in obesity and insulin resistance. J Clin Endocrinol Metab. 2011;96:E1990–E8.
150. Sung HK, Doh KO, Son JE, et al. Adipose vascular endothelial growth factor regulates metabolic homeostasis through angiogenesis. Cell Metab. 2013;17:61–72.
151. Ye JP, Gao ZG, Yin J, et al. Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am J Physiol Endocrinol Metab. 2007;293:E1118–E28.
152. Hosogai N, Fukuhara A, Oshima K, et al. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes. 2007;56:901–11.
153. Wang B, Wood IS, Trayhurn P. Dysregulation of the expression and secretion of inflammation-related adipokines by hypoxia in human adipocytes. Pflugers Arch. 2007;455:479–92.
154. Alvarez-Llamas G, Szalowska E, de Vries MP, et al. Characterization of the human visceral adipose tissue secretome. Mol Cell Proteomics. 2007;6:589–600.
155. Silha JV, Krsek M, Sucharda P, et al. Angiogenic factors are elevated in overweight and obese individuals. Int J Obes (Lond). 2005;29:1308–14.
156. Voros G, Lijnen HR. Deficiency of thrombospondin-1 in mice does not affect adipose tissue development. J Thromb Haemost. 2006;4:277–8.
157. Lakeland TV, Borg ML, Matzaris M, et al. Augmented expression and secretion of adipose-derived pigment epithelium-derived factor does not alter local angiogenesis or contribute to the development of systemic metabolic derangements. Am J Physiol Endocrinol Metab. 2014;306:E1367–E77.